Drug Trial Radar · NCT06730022
Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds
Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Merakris TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.
Conditions
- Cutaneous Ulcer
- Diabetic Ulcer
- Surgical Wound Dehiscence
- Burns - Multiple
- Pressure Ulcers
- Mixed Ulcer
- Ischemic Ulcer
Interventions
MTX-001 (Dermacyte Liquid)Drug
Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The WISH Clinic
Arvada, Colorado · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.